(Q40674501)

22 September 2017

1 reference

title

Standard treatment of multiple myeloma (English)

1 reference

22 September 2017

M M Oken

1

1 reference

PubMed ID

8035637

22 September 2017

language of work or name

English

0 references

publication date

1 August 1994

1 reference

22 September 2017

1 reference

22 September 2017

69

1 reference

22 September 2017

781-786

1 reference

22 September 2017

8

1 reference

Combination chemotherapy for multiple myeloma

22 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute Leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three- and five-drug combinations: an Argentine Group for the Treatment of Acute Leukemia Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

Interferon therapy in myelomatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

Interferon in the Treatment of Refractory Multiple Myeloma: An Eastern Cooperative Oncology Group Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

Results of the MRC myelomatosis trials for patients entered since 1980

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

Second and third responses to the same induction regimen in relapsing patients with multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

High-dose glucocorticoid treatment of resistant myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

High-dose dexamethasone for refractory or relapsing multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961100-8

10.1016/S0025-6196(12)61100-8

7 January 2021

Identifiers

DOI

1 reference

22 September 2017

1 reference

PubMed ID

8035637